Compare Amgen, Inc. (AMGN) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Select Medical Holdings Corporation — how do they compare? Amgen, Inc. trades at $356.38 (market cap $196.12B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Amgen, Inc. is far larger — about 95.7× Select Medical Holdings Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SEM | |
|---|---|---|
Market Cap | $196.12B | $2.05B |
Sector | Health | Health |
52-Week High | $388.16 | $16.66 |
52-Week Low | $271.18 | $11.77 |
Enterprise Value | $241.41B | $5.01B |
Dividend Yield | 2.77% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following the company's recent acquisition by a consortium led by Robert A. Ortenzio at $16.50 per share. The stock shows mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company reported $5.45B revenue for 2025 with a 2.42% net margin, while valuation metrics appear reasonable with a P/E of 15.43 and P/S of 0.36. Recent earnings have been mixed with one beat and two misses against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the current price. While fundamentals show stable operations with positive cash flow from operations, multiple law firms are investigating potential fiduciary breaches in the buyout process. Analyst sentiment is mixed with 35.7% buy ratings, but the acquisition removes typical growth catalysts. Key risks include legal challenges to the merger terms and execution risks during the ownership transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
